ctDNA
MyJourneywithCancer
CSN Member Posts: 82
This recent publication showed a cost effective, noninvasive way to determine genetic alterations in metastatic Bladder Cancer. The authors found DNA sequencing from tumor DNA circulating in plasma reveled driver mutations that are often target-able by drugs. http://clincancerres.aacrjournals.org/content/early/2017/08/04/1078-0432.CCR-17-1140
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 122.3K Cancer specific
- 2.8K Anal Cancer
- 451 Bladder Cancer
- 310 Bone Cancers
- 1.6K Brain Cancer
- 28.5K Breast Cancer
- 399 Childhood Cancers
- 27.9K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.2K Gynecological Cancers (other than ovarian and uterine)
- 13K Head and Neck Cancer
- 6.4K Kidney Cancer
- 677 Leukemia
- 799 Liver Cancer
- 4.2K Lung Cancer
- 5.1K Lymphoma (Hodgkin and Non-Hodgkin)
- 240 Multiple Myeloma
- 7.2K Ovarian Cancer
- 65 Pancreatic Cancer
- 492 Peritoneal Cancer
- 5.6K Prostate Cancer
- 1.2K Rare and Other Cancers
- 544 Sarcoma
- 740 Skin Cancer
- 659 Stomach Cancer
- 192 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.9K Uterine/Endometrial Cancer
- 6.3K Lifestyle Discussion Boards